Global Penicillin and Streptomycin Market, 2025-2035

Description

List of Tables

Global Penicillin and Streptomycin Market Size, Share & Trends Analysis by Product Type (Penicillin, and Streptomycin), By Manufacturing Process (Natural, Semi-synthetic, and Synthetic), By Route of Administration (Oral, Intramuscular, and Intravenous), By Application (Therapeutic Use, Laboratory / Cell Culture Use, Veterinary Use, and Others) and By End-User (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Research & Academic Institutes, Veterinary Facilities, and Others), Forecast Period (2026-2035)

Industry Overview

Penicillin and streptomycin market was valued at $3.3 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 7.0% during the forecast Period (2026-2035). The market represents a mature yet essential segment of the antibiotics industry, driven by consistent demand for effective treatment of bacterial infections. These antibiotics are widely used across hospitals, clinics, and research laboratories due to their proven efficacy and affordability. In addition to therapeutic applications, they play a key role in cell culture and biopharmaceutical production. Market growth is supported by rising infection rates, expanding healthcare access, and continued relevance in both human and veterinary medicine.

Market Dynamics

Rising Prevalence of Infectious and Bacterial Diseases

The increasing global burden of infectious diseases, particularly bacterial infections such as tuberculosis, meningitis, and respiratory infections, is a primary driver of the penicillin and streptomycin market. These antibiotics remain essential due to their broad-spectrum effectiveness against both gram-positive and gram-negative bacteria. Growing incidence rates, especially in low- and middle-income countries, continue to create sustained demand for cost-effective and reliable antibiotic therapies, thereby significantly boosting market growth.

Expansion of Pharmaceutical and Biotechnology Industries

The rapid growth of the pharmaceutical and biotechnology sectors is another major driver, as penicillin and streptomycin are widely used in drug manufacturing and cell culture applications to prevent microbial contamination. Increasing investments in biologics, vaccine production, and R&D activities are further accelerating demand. Additionally, the routine use of these antibiotics in research laboratories and biopharma processes strengthens their commercial relevance beyond clinical therapeutics.

Increasing Demand from Healthcare Infrastructure and Hospital Settings

The expansion of healthcare infrastructure, along with rising hospital admissions and surgical procedures, is driving higher consumption of antibiotics. Penicillin and streptomycin are extensively used in hospitals to manage infections and prevent hospital-acquired infections (HAIs). Growing awareness of infection control, coupled with the increasing need for effective first-line antibiotic treatments, continues to support market growth, particularly in emerging economies with improving healthcare access.

Market Segmentation

Based on the product type, the market is segmented into penicillin and streptomycin.
Based on the manufacturing process, the market is segmented into natural, semi-synthetic, and synthetic.
Based on the route of administration, the market is segmented into oral, intramuscular, and intravenous.
Based on the application, the market is segmented into therapeutic use, laboratory/cell culture use, veterinary use, and others.
Based on the end-user, the market is segmented into hospitals, clinics, retail pharmacies, online pharmacies, research & academic institutes, veterinary facilities, and others.

Therapeutic Use Segment to Grow at a Considerable Market Share

The therapeutic use segment is expected to dominate the global penicillin and streptomycin market as the largest segment across all categories, primarily due to the continued and widespread reliance on these antibiotics for the treatment of bacterial infections. Penicillin remains one of the most commonly prescribed antibiotics globally for conditions such as respiratory tract infections, skin infections, and sexually transmitted diseases, while streptomycin is critically used in the treatment of tuberculosis and other severe infections. The high global burden of infectious diseases, particularly in developing regions, ensures consistent and large-scale consumption of these drugs in clinical settings.

Moreover, therapeutic applications generate significantly higher and more consistent revenue compared to laboratory or veterinary uses, as they are directly linked to patient treatment volumes in hospitals and clinics. The increasing number of hospital admissions, rising surgical procedures, and growing awareness regarding early infection treatment further strengthen this segment's dominance. In addition, government initiatives to improve access to essential medicines and the inclusion of penicillin-class antibiotics in essential drug lists across many countries reinforce their large-scale therapeutic use. As a result, the therapeutic use segment continues to lead the market in terms of both demand and revenue contribution.

Penicillin: A Key Segment in Market Growth

The Penicillin segment under product type is expected to be the key contributor to market growth in the global penicillin and streptomycin market. This dominance is primarily attributed to penicillin's broad-spectrum efficacy, cost-effectiveness, and long-standing clinical acceptance in treating a wide range of bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases. Its widespread availability in multiple formulations, oral, injectable, and intravenous, enhances its accessibility across different healthcare settings, further strengthening its adoption. In addition, penicillin remains a first-line treatment in many developing and emerging economies due to its affordability compared to newer antibiotics, making it highly preferred in regions with constrained healthcare budgets. The segment also benefits from strong demand in hospital settings where it is frequently used for both treatment and prophylaxis of infections, particularly during surgeries.

Moreover, increasing government initiatives aimed at improving access to essential medicines and expanding antibiotic availability are further supporting the growth of the penicillin segment. Its continued use in both human and veterinary medicine, along with its role in combating common bacterial infections, ensures sustained demand, making it the most significant driver of overall market expansion within the product type category.

Regional Outlook

The global penicillin and streptomycin market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global penicillin and streptomycin market, holding a major share due to its advanced healthcare infrastructure, strong pharmaceutical manufacturing base, and high antibiotic consumption rates. The country benefits from the presence of leading pharmaceutical and biotechnology companies that actively produce and distribute a wide range of antibiotic formulations, including penicillin derivatives and streptomycin. In addition, the high prevalence of bacterial infections, coupled with well-established diagnostic and treatment frameworks, supports consistent demand for these antibiotics. The US also has a robust research ecosystem, where penicillin and streptomycin are widely utilized in laboratory applications, cell culture processes, and drug development activities, further expanding their market scope beyond therapeutic use. Favorable regulatory support and continuous investments in healthcare innovation contribute to sustained product availability and quality standards.

Moreover, strong distribution networks, including hospital pharmacies, retail chains, and online platforms, ensure widespread accessibility across the country. The growing focus on infection control, particularly in hospital settings, and the increasing number of surgical procedures also drive antibiotic usage. Despite concerns regarding antimicrobial resistance, the continued reliance on established antibiotics for first-line treatment in specific conditions reinforces the United States' leading position in the global market.

Market Players Outlook

The major companies operating in the global penicillin and streptomycin market include Aurobindo Pharma Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Pfizer Inc., Sandoz Group AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

In March 2026, the World Health Organization (WHO) released new Target Product Profiles (TPPs) for urgently needed antibiotics to address antimicrobial resistance, reinforcing the continued importance of existing antibiotics such as penicillin and streptomycin while promoting innovation in next-generation therapies.

The Report Covers:

Market value data analysis for 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global penicillin and streptomycin market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market

Product Code: OMR2029356

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Penicillin and Streptomycin Market Sales Analysis - Product Type | Manufacturing Process | Route of Administration | Application | End-User ($ Million)
Penicillin and Streptomycin Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Penicillin and Streptomycin Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Penicillin and Streptomycin Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Penicillin and Streptomycin Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Penicillin and Streptomycin Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Penicillin and Streptomycin Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Penicillin and Streptomycin Market Revenue and Share by Manufacturers
Penicillin and Streptomycin Manufacturing Process Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Aurobindo Pharma Ltd.
  - 4.2.1.1. Overview
  - 4.2.1.2. Manufacturing Process Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. GlaxoSmithKline plc (GSK)
  - 4.2.2.1. Overview
  - 4.2.2.2. Manufacturing Process Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Merck & Co., Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Manufacturing Process Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Pfizer Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Manufacturing Process Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sandoz Group AG
  - 4.2.5.1. Overview
  - 4.2.5.2. Manufacturing Process Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Manufacturing Process Launch
- 4.3.3. Partnership And Collaboration

5. Global Penicillin and Streptomycin Market Sales Analysis by Product Type ($ Million)

5.1. Penicillin
5.2. Streptomycin

6. Global Penicillin and Streptomycin Market Sales Analysis by Manufacturing Process ($ Million)

6.1. Natural
6.2. Semi-synthetic
6.3. Synthetic

7. Global Penicillin and Streptomycin Market Sales Analysis by Route of Administration ($ Million)

7.1. Oral
7.2. Intramuscular
7.3. Intravenous

8. Global Penicillin and Streptomycin Market Sales Analysis by Application ($ Million)

8.1. Therapeutic Use
8.2. Laboratory / Cell Culture Use
8.3. Veterinary Use
8.4. Others

9. Global Penicillin and Streptomycin Market Sales Analysis by End-User ($ Million)

9.1. Hospitals
9.2. Clinics
9.3. Retail Pharmacies
9.4. Online Pharmacies
9.5. Research & Academic Institutes
9.6. Veterinary Facilities
9.7. Others

10. Regional Analysis

10.1. North American Penicillin and Streptomycin Market Sales Analysis - Product Type | Manufacturing Process | Route of Administration | Application | End-User | Country ($ Million)
Macroeconomic Factors for North America
- 10.1.1. United States
- 10.1.2. Canada
10.2. European Penicillin and Streptomycin Market Sales Analysis - Product Type | Manufacturing Process | Route of Administration | Application | End-User | Country ($ Million)
Macroeconomic Factors for Europe
- 10.2.1. UK
- 10.2.2. Germany
- 10.2.3. Italy
- 10.2.4. Spain
- 10.2.5. France
- 10.2.6. Russia
- 10.2.7. Rest of Europe
10.3. Asia-Pacific Penicillin and Streptomycin Market Sales Analysis - Product Type | Manufacturing Process | Route of Administration | Application | End-User | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. South Korea
- 10.3.4. India
- 10.3.5. Australia & New Zealand
- 10.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 10.3.7. Rest of Asia-Pacific
10.4. Rest of the World Penicillin and Streptomycin Market Sales Analysis - Product Type | Manufacturing Process | Route of Administration | Application | End-User | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 10.4.1. Latin America
- 10.4.2. Middle East and Africa

11. Company Profiles

11.1. Abbott Laboratories
- 11.1.1. Quick Facts
- 11.1.2. Company Overview
- 11.1.3. Product Portfolio
- 11.1.4. Business Strategies
11.2. Alkem Laboratories Ltd.
- 11.2.1. Quick Facts
- 11.2.2. Company Overview
- 11.2.3. Product Portfolio
- 11.2.4. Business Strategies
11.3. Astellas Pharma Inc.
- 11.3.1. Quick Facts
- 11.3.2. Company Overview
- 11.3.3. Product Portfolio
- 11.3.4. Business Strategies
11.4. AstraZeneca plc
- 11.4.1. Quick Facts
- 11.4.2. Company Overview
- 11.4.3. Product Portfolio
- 11.4.4. Business Strategies
11.5. Aurobindo Pharma Ltd.
- 11.5.1. Quick Facts
- 11.5.2. Company Overview
- 11.5.3. Product Portfolio
- 11.5.4. Business Strategies
11.6. Bayer AG
- 11.6.1. Quick Facts
- 11.6.2. Company Overview
- 11.6.3. Product Portfolio
- 11.6.4. Business Strategies
11.7. Cipla Ltd.
- 11.7.1. Quick Facts
- 11.7.2. Company Overview
- 11.7.3. Product Portfolio
- 11.7.4. Business Strategies
11.8. Dr. Reddy's Laboratories, Inc.
- 11.8.1. Quick Facts
- 11.8.2. Company Overview
- 11.8.3. Product Portfolio
- 11.8.4. Business Strategies
11.9. Eli Lilly and Co.
- 11.9.1. Quick Facts
- 11.9.2. Company Overview
- 11.9.3. Product Portfolio
- 11.9.4. Business Strategies
11.10. GSK plc
- 11.10.1. Quick Facts
- 11.10.2. Company Overview
- 11.10.3. Product Portfolio
- 11.10.4. Business Strategies
11.11. Johnson & Johnson
- 11.11.1. Quick Facts
- 11.11.2. Company Overview
- 11.11.3. Product Portfolio
- 11.11.4. Business Strategies
11.12. Lonza AG
- 11.12.1. Quick Facts
- 11.12.2. Company Overview
- 11.12.3. Product Portfolio
- 11.12.4. Business Strategies
11.13. Merck & Co., Inc.
- 11.13.1. Quick Facts
- 11.13.2. Company Overview
- 11.13.3. Product Portfolio
- 11.13.4. Business Strategies
11.14. Pfizer, Inc.
- 11.14.1. Quick Facts
- 11.14.2. Company Overview
- 11.14.3. Product Portfolio
- 11.14.4. Business Strategies
11.15. Sandoz Group AG
- 11.15.1. Quick Facts
- 11.15.2. Company Overview
- 11.15.3. Product Portfolio
- 11.15.4. Business Strategies
11.16. Sanofi S.A.
- 11.16.1. Quick Facts
- 11.16.2. Company Overview
- 11.16.3. Product Portfolio
- 11.16.4. Business Strategies
11.17. Shionogi & Co., Ltd.
- 11.17.1. Quick Facts
- 11.17.2. Company Overview
- 11.17.3. Product Portfolio
- 11.17.4. Business Strategies
11.18. Sun Pharmaceutical Industries Ltd.
- 11.18.1. Quick Facts
- 11.18.2. Company Overview
- 11.18.3. Product Portfolio
- 11.18.4. Business Strategies
11.19. Takeda Pharmaceutical Co. Ltd.
- 11.19.1. Quick Facts
- 11.19.2. Company Overview
- 11.19.3. Product Portfolio
- 11.19.4. Business Strategies
11.20. Teva Pharmaceutical Industries Ltd.
- 11.20.1. Quick Facts
- 11.20.2. Company Overview
- 11.20.3. Product Portfolio
- 11.20.4. Business Strategies